search
Back to results

A Phase I Study of BR108 in Hematological Malignancies

Primary Purpose

Hematologic Malignancy

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
BR108 injection
Sponsored by
BioRay Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hematologic Malignancy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 1. Voluntary agreement to provide written informed consent; 2. Males and females who are ≥18 years old; 3. Patients must have an advanced hematologic malignancy including: Relapsed or refractory lymphoma as defined by World Health Organization(WHO) criteria; Relapsed or refractory AML /MDSas defined by World Health Organization (WHO) criteria; 4. Subjects must have documented CD70-positive . 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 7. Expected survival time ≥3 months; 8.Have at least 1 evaluable lesion per Lugano 2014; 9. The function of major organs must meet the following criteria (Lymphoma:have not received blood transfusion, EPO, G-CSF or other medical supportive treatment within 7 days before the first dose of study drug) : White blood cell count≤25×109/L(for AML/MDS) Absolute neutrophil count (ANC) ≥1.5×109/L or ≥0.75×109 /L for patients with bone marrow infiltration, Platelet ≥75×109 /L or ≥50×109 /L for patients with bone marrow infiltration; Hemoglobin ≥8.0mmol/L or ≥ 7.0mmol/L for patients with bone marrow infiltration; International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN; Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN; serum creatinine≤1.5×ULN or Creatinine clearance rate ≥60 mL/min ; Total bilirubin ≤1.5×ULN or ≤3×ULN for patients with Gilbert's syndrome or liver metastasis; Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5×ULN or ≤5×ULN for patients with liver metastasis: 10. Women of child bearing potential and non-sterilized male patients who are sexually active with a female partner of child bearing potential must agree to use an effective method of contraception from screening until 6 months after the last dose of study drug. Effective methods of contraception consist of prior sterilization, intrauterine device, intrauterine hormone-releasing system, oral or injectable contraceptives, and sexual abstinence. 11. Patients will be able to communicate well with the investigator, understand and comply with the requirements of the study. Exclusion Criteria: 1. Pregnant or lactating women; 2. Acute promyelocytic leukemia, acute transformation of chronic myeloid leukemia, primary central nervous system malignancies or invasion of the central nervous system (except for those who are asymptomatic or stable and do not require treatment ≥4 weeks before the first dose of study drug); 3. Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ grade 1 or baseline (refer to NCICTCAE5.0 ), except for alopecia, pigmentation and other toxicity judged no safety risk by the investigator; 4. Previous exposure to CD70-targeted agents; 5. Patients with Allergic history or hypersensitivity reaction to any components of BR108 injection; 6. Patients with active bacterial, viral, fungal, mycobacterium, parasite or other infection (except fungal infection of nail bed) within 7 days prior to enrollment and requiring intravenous infusion therapy (except neoplastic fever); 7. Patients with inherited or acquired hemorrhagic diseases or severe coagulation abnormalities of clinical significance( Such as diffuse intravascular coagulation (DIC) autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, sickle cell anemia, etc); 8. HBsAg or HBcAb positive, and HBV DNA positive; HCVAb positive and HCV RNA positive; HIV positive; syphilis infection requiring systematic treatment ; 9. Subjects who have received live or attenuated vaccine within 4 weeks before the first administration or planned to receive live vaccine during the study period; 10. History of any other malignancies within 3 years (except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, localized prostate cancer, cervical carcinoma in situ, stage I ductal carcinoma in situ of the breast, and malignancies that have been cured (CR) within 2 years prior to initial administration and are currently considered stable by the investigator with minimal risk of recurrence); 11. Patients with serious cardiovascular and cerebrovascular diseases or other serious organic diseases, including but not limited to: History of stroke 、intracranial hemorrhage 、unstable angina pectoris、 congestive heart failure (NYHA III-IV)、myocardial infarction、severe arrhythmias (e.g., persistent ventricular tachycardia, ventricular fibrillation) or congenital long QT syndrome within 6 months before enrollment. Left ventricular ejection fraction (LVEF) < 50% in echocardiography (ECHO) or muti-gate detection scan (MUGA) . Corrected QT interval prolongation >470ms. Patients with interstitial lung disease, severe lung dysfunction, severe pulmonary fibrosis, or pulmonary infection requiring systematic treatment. 12. Subjects who have autoimmune disorders and need to rely on immunosuppressive therapy or receive systemic therapy with a dose of ≥20mg/day of prednisone or other equivalent hormones within 2 weeks before enrollment; 13. Patients have received other clinical trials within 4 weeks before the first dose of study drug; 14.Subjects who have major surgery or severe trauma within 4 weeks prior to initial dosing or plan to take major surgery during the trial period; 15. Treatment with prior anti-cancer therapy (including chemotherapy, endocrine therapy, targeted therapy, etc.) must have been terminated at last 28 days or 5 half-lives (whichever is shorter) before study enrolment,2 weeks for endocrine therapy and Chinese medicine treatment with anti-tumor indications or local palliative radiotherapy for bone metastasis and pain relief within 2 weeks. 16. Prior allogeneic hematopoietic stem cell or organ transplantation; recent Autologous hematopoietic stem cell transplantation(less than 3 months prior first dosing of study drug); 17. Patients with any mental or cognitive impairment that may restrict the understanding and implementation of the informed consent; 18. Other serious, uncontrollable concomitant diseases that may affect protocol compliance or interfere with outcomes, or other serious or uncontrollable medical conditions that the investigator believes may put subjects at risk for participating in the study

Sites / Locations

  • Tianjin Medical University Cancer Institute and HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BR108

Arm Description

Outcomes

Primary Outcome Measures

Number of Participants with Dose Limiting Toxicity (DLT)
Dose limiting toxicity
objective response rate(ORR)
FOR lymphoma ,Objective Response Rate is defined as the percentage of patients with a complete response (CR) or partial response (PR). For AML, the proportion of participants who achieve a best response of CR, CRi, MLFS, or partial response (PR). For MDS, the proportion of participants who achieve a best response of CR, marrow CR, or PR.

Secondary Outcome Measures

Cmax
Cmax is the maximum observed concentration.
Tmax
Time to maximum concentration attained
Incidence of antidrug antibodies (ADA)
Percentage of patients producing detectable ADA
Duration of remission (DOR)
To preliminarily evaluate DoR in patients with hematological malignancies

Full Information

First Posted
August 11, 2023
Last Updated
August 25, 2023
Sponsor
BioRay Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT06018506
Brief Title
A Phase I Study of BR108 in Hematological Malignancies
Official Title
A Phase I ,Single-arm, Open-label Study to Evalute the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Clinical Activity of BR108 Injection in Subjects With Hematological Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 27, 2023 (Actual)
Primary Completion Date
October 21, 2024 (Anticipated)
Study Completion Date
March 2, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioRay Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A Phase I study of BR108 in hematological malignancies

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematologic Malignancy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BR108
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BR108 injection
Intervention Description
Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
Primary Outcome Measure Information:
Title
Number of Participants with Dose Limiting Toxicity (DLT)
Description
Dose limiting toxicity
Time Frame
up to 28 days
Title
objective response rate(ORR)
Description
FOR lymphoma ,Objective Response Rate is defined as the percentage of patients with a complete response (CR) or partial response (PR). For AML, the proportion of participants who achieve a best response of CR, CRi, MLFS, or partial response (PR). For MDS, the proportion of participants who achieve a best response of CR, marrow CR, or PR.
Time Frame
up to approximately 3 years
Secondary Outcome Measure Information:
Title
Cmax
Description
Cmax is the maximum observed concentration.
Time Frame
up to approximately 3 years
Title
Tmax
Description
Time to maximum concentration attained
Time Frame
up to approximately 3 years
Title
Incidence of antidrug antibodies (ADA)
Description
Percentage of patients producing detectable ADA
Time Frame
up to approximately 3 years
Title
Duration of remission (DOR)
Description
To preliminarily evaluate DoR in patients with hematological malignancies
Time Frame
up to approximately 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Voluntary agreement to provide written informed consent; 2. Males and females who are ≥18 years old; 3. Patients must have an advanced hematologic malignancy including: Relapsed or refractory lymphoma as defined by World Health Organization(WHO) criteria; Relapsed or refractory AML /MDSas defined by World Health Organization (WHO) criteria; 4. Subjects must have documented CD70-positive . 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 7. Expected survival time ≥3 months; 8.Have at least 1 evaluable lesion per Lugano 2014; 9. The function of major organs must meet the following criteria (Lymphoma:have not received blood transfusion, EPO, G-CSF or other medical supportive treatment within 7 days before the first dose of study drug) : White blood cell count≤25×109/L(for AML/MDS) Absolute neutrophil count (ANC) ≥1.5×109/L or ≥0.75×109 /L for patients with bone marrow infiltration, Platelet ≥75×109 /L or ≥50×109 /L for patients with bone marrow infiltration; Hemoglobin ≥8.0mmol/L or ≥ 7.0mmol/L for patients with bone marrow infiltration; International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN; Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN; serum creatinine≤1.5×ULN or Creatinine clearance rate ≥60 mL/min ; Total bilirubin ≤1.5×ULN or ≤3×ULN for patients with Gilbert's syndrome or liver metastasis; Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5×ULN or ≤5×ULN for patients with liver metastasis: 10. Women of child bearing potential and non-sterilized male patients who are sexually active with a female partner of child bearing potential must agree to use an effective method of contraception from screening until 6 months after the last dose of study drug. Effective methods of contraception consist of prior sterilization, intrauterine device, intrauterine hormone-releasing system, oral or injectable contraceptives, and sexual abstinence. 11. Patients will be able to communicate well with the investigator, understand and comply with the requirements of the study. Exclusion Criteria: 1. Pregnant or lactating women; 2. Acute promyelocytic leukemia, acute transformation of chronic myeloid leukemia, primary central nervous system malignancies or invasion of the central nervous system (except for those who are asymptomatic or stable and do not require treatment ≥4 weeks before the first dose of study drug); 3. Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ grade 1 or baseline (refer to NCICTCAE5.0 ), except for alopecia, pigmentation and other toxicity judged no safety risk by the investigator; 4. Previous exposure to CD70-targeted agents; 5. Patients with Allergic history or hypersensitivity reaction to any components of BR108 injection; 6. Patients with active bacterial, viral, fungal, mycobacterium, parasite or other infection (except fungal infection of nail bed) within 7 days prior to enrollment and requiring intravenous infusion therapy (except neoplastic fever); 7. Patients with inherited or acquired hemorrhagic diseases or severe coagulation abnormalities of clinical significance( Such as diffuse intravascular coagulation (DIC) autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, sickle cell anemia, etc); 8. HBsAg or HBcAb positive, and HBV DNA positive; HCVAb positive and HCV RNA positive; HIV positive; syphilis infection requiring systematic treatment ; 9. Subjects who have received live or attenuated vaccine within 4 weeks before the first administration or planned to receive live vaccine during the study period; 10. History of any other malignancies within 3 years (except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, localized prostate cancer, cervical carcinoma in situ, stage I ductal carcinoma in situ of the breast, and malignancies that have been cured (CR) within 2 years prior to initial administration and are currently considered stable by the investigator with minimal risk of recurrence); 11. Patients with serious cardiovascular and cerebrovascular diseases or other serious organic diseases, including but not limited to: History of stroke 、intracranial hemorrhage 、unstable angina pectoris、 congestive heart failure (NYHA III-IV)、myocardial infarction、severe arrhythmias (e.g., persistent ventricular tachycardia, ventricular fibrillation) or congenital long QT syndrome within 6 months before enrollment. Left ventricular ejection fraction (LVEF) < 50% in echocardiography (ECHO) or muti-gate detection scan (MUGA) . Corrected QT interval prolongation >470ms. Patients with interstitial lung disease, severe lung dysfunction, severe pulmonary fibrosis, or pulmonary infection requiring systematic treatment. 12. Subjects who have autoimmune disorders and need to rely on immunosuppressive therapy or receive systemic therapy with a dose of ≥20mg/day of prednisone or other equivalent hormones within 2 weeks before enrollment; 13. Patients have received other clinical trials within 4 weeks before the first dose of study drug; 14.Subjects who have major surgery or severe trauma within 4 weeks prior to initial dosing or plan to take major surgery during the trial period; 15. Treatment with prior anti-cancer therapy (including chemotherapy, endocrine therapy, targeted therapy, etc.) must have been terminated at last 28 days or 5 half-lives (whichever is shorter) before study enrolment,2 weeks for endocrine therapy and Chinese medicine treatment with anti-tumor indications or local palliative radiotherapy for bone metastasis and pain relief within 2 weeks. 16. Prior allogeneic hematopoietic stem cell or organ transplantation; recent Autologous hematopoietic stem cell transplantation(less than 3 months prior first dosing of study drug); 17. Patients with any mental or cognitive impairment that may restrict the understanding and implementation of the informed consent; 18. Other serious, uncontrollable concomitant diseases that may affect protocol compliance or interfere with outcomes, or other serious or uncontrollable medical conditions that the investigator believes may put subjects at risk for participating in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhang Huilai, PhD
Phone
18622221228
Email
huilaizhangtz@163.com
Facility Information:
Facility Name
Tianjin Medical University Cancer Institute and Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhang Huilai, PhD
Phone
18622221228
Email
huilaizhangtz@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Phase I Study of BR108 in Hematological Malignancies

We'll reach out to this number within 24 hrs